13D Filing: Aisling Capital III LP and Transenterix Inc. (TRXC)

Page 8 of 12

Page 8 of 12 – SEC Filing

CUSIP No. 89366M102
SCHEDULE 13D/A
Page 8 of 12
Item 1.
Security and Issuer.
This Amendment No. 5 to Schedule 13D (this Statement) amends and supplements the Schedule 13D as previously filed by the undersigned Reporting Persons (as defined below) on September 13, 2013, and amended by Amendment No. 1 to the Schedule 13D, filed by the Reporting Persons on December 10, 2013, Amendment No. 2 to the Schedule 13D, filed by the Reporting Persons on April 23, 2014, by Amendment No. 3 to the Schedule 13D, filed by the Reporting Persons on February 5, 2016 and Amendment No. 4 filed by the Reporting Persons on May 9, 2017, with respect to the Common Stock, $0.001 par value (the Common Stock), of TransEnterix, Inc. (f/k/a SafeStitch Medical, Inc. and Cellular Technical Services Company, Inc.), a Delaware corporation (the Issuer). The principal executive office of the Issuer is located at 635 Davis Drive, Suite 300, Durham, North Carolina 27713.
Item 2.
Identity and Background.
No material change.
Item 3.
Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended and supplemented as follows:
On October 18, 2017, Aisling exercised the Series A Warrants at an exercise price of $1.00 and received 2,000,000 shares of Common Stock.  The source of the exercise price paid for the shares was capital contributions from the partners of Aisling. No borrowed funds were used by Aisling in connection with the exercise of the Series A Warrants.

Follow Asensus Surgical Inc. (NYSEMKT:ASXC)

Page 8 of 12